AVE-1642
AVE-1642 is a monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R), which is implicated in the growth and survival of various cancer cells. This investigational drug is being studied for its potential use in the treatment of several types of cancer, including breast cancer, prostate cancer, and non-small cell lung cancer.
Mechanism of Action[edit | edit source]
AVE-1642 functions by binding to the IGF-1R, a receptor that is overexpressed in many tumors. The binding of AVE-1642 to IGF-1R inhibits the receptor's ability to interact with its natural ligands, insulin-like growth factor 1 (IGF-1) and insulin-like growth factor 2 (IGF-2). This inhibition blocks the downstream signaling pathways that promote cell proliferation and survival, such as the PI3K/AKT/mTOR pathway and the Ras/Raf/MEK/ERK pathway.
Clinical Development[edit | edit source]
AVE-1642 has undergone several clinical trials to evaluate its safety and efficacy. Early-phase trials have focused on its use as a monotherapy and in combination with other anticancer agents. Results have shown that AVE-1642 is generally well-tolerated, with manageable side effects. However, further studies are needed to fully establish its clinical benefits and optimal use in cancer therapy.
Potential Benefits[edit | edit source]
The targeting of IGF-1R by AVE-1642 offers a promising therapeutic strategy, particularly for tumors that are resistant to conventional therapies. By inhibiting a key growth and survival pathway, AVE-1642 may enhance the effectiveness of existing treatments and improve patient outcomes.
Challenges and Considerations[edit | edit source]
Despite its potential, the development of AVE-1642 faces several challenges. The redundancy and complexity of the IGF signaling network can lead to compensatory mechanisms that diminish the drug's effectiveness. Additionally, identifying patients who are most likely to benefit from IGF-1R inhibition remains a critical area of research.
Also see[edit | edit source]
- Monoclonal antibody therapy
- Cancer immunotherapy
- Targeted therapy
- Insulin-like growth factor 1 receptor
- PI3K/AKT/mTOR pathway
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
